drugset / Trial / NCT06745297

A Study in Healthy Men to Test How Well Different Doses of BI 3776528 Are Tolerated

NCT06745297 ↗

Phase 1 Recruiting 172 enrolled Boehringer Ingelheim
RandomizedSequentialSingle-blindTreatment

Summary

The trial aims to study the safety, tolerability, and pharmacokinetics of single and multiple rising doses of BI 3776528.

Timeline

Start
2025-01-23
Primary completion
2027-02-03
Completion
2027-02-03

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 3776528 Unknown — —

Indications

No indication recorded.